Filing Flows › NovoCure (NVCR) › Q1 2025
NovoCure (NVCR) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 24, 2025
NovoCure (NVCR) reported revenue of $155M for the first quarter 2025 (Q1 2025), +12% from a year earlier and -4% from the quarter before. Operating margin was -24.4%, net loss $34.3M (22.1% of revenue).
NovoCure, Q1 2025: revenue $155M (+12% year over year), operating margin -24.4%, net loss $34.3M, operating cash flow −$35.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $155M | -4% | +12% |
| Operating profit | −$37.9M | — | — |
| Net earnings | −$34.3M | — | — |
| Operating cash flow | −$35.7M | — | — |
What changed
Revenue was $155.0M in Q1 2025, up 12% year over year and down 4% from the previous quarter.
Gross margin was 75.1%, down 0.5 points from a year earlier. Operating costs exceeded revenue by $37.9M, an operating margin of -24.4%. Operating expenses grew 5% against revenue growth of 12%. The fastest-growing cost line was General & admin (+13%). The quarter ended with a net loss of $34.3M, narrower than the previous quarter's $65.9M loss. Non-operating items added $7.6M, -25% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$35.7M. Non-cash charges added back $3.3M of depreciation and amortization and $29.6M of share-based compensation. Working capital and other items used $34.2M. Capital expenditures of $10.6M exceeded it, leaving free cash flow of −$46.3M.
Questions
What was NovoCure's revenue in the first quarter 2025?
NovoCure (NVCR) reported revenue of $155M for the first quarter 2025 (Q1 2025), +12% from a year earlier and -4% from the quarter before.
Was NovoCure profitable in the first quarter 2025?
Operating loss was $37.9M (-24.4% of revenue) and net loss $34.3M.
Source: NovoCure 10-Q on SEC EDGAR.